Tag: warning letters

How to Write an Inspection-Ready GMP Audit Response That Satisfies FDA and EMA Comprehensive Guide to Writing Inspection-Ready Responses for FDA 483 and GMP Audits Responding effectively to a FDA 483 observation or equivalent findings from a GMP inspection conducted by regulatory authorities such as the FDA, EMA, or MHRA is a critical skill for…

Read More “How to Write an Inspection-Ready GMP Audit Response That Satisfies FDA and EMA” »

FDA Warning Letters for GMP Failures: Common Themes and Lessons for QA Leaders Understanding FDA Warning Letters for GMP Failures: A Step-by-Step Guide for Pharma QA Leaders Within the pharmaceutical industry, FDA 483 observations and subsequent warning letters serve as critical indicators of compliance status following GMP inspections and audits. For professionals working in pharma…

Read More “FDA Warning Letters for GMP Failures: Common Themes and Lessons for QA Leaders” »

Pre-Approval Inspections (PAI) in Pharma: Documentation, Data and Shop-Floor Readiness Step-by-Step Guide to Pre-Approval Inspections: Ensuring Documentation, Data, and Shop-Floor Readiness Pre-Approval Inspections (PAI) are critical milestones in the pharmaceutical manufacturing lifecycle, conducted by regulatory authorities to assess a facility’s compliance with current Good Manufacturing Practice (cGMP) before marketing approval of a drug product or…

Read More “Pre-Approval Inspections (PAI) in Pharma: Documentation, Data and Shop-Floor Readiness” »

EU GMP and MHRA Inspections: Key Focus Areas for US-Based Sites Preparing US-Based Pharmaceutical Sites for EU GMP and MHRA Inspections: A Step-by-Step GMP Tutorial The pharmaceutical industry operates within a stringent global regulatory framework, where compliance with Good Manufacturing Practice (GMP) standards is mandatory to ensure product quality, patient safety, and market access. US-based…

Read More “EU GMP and MHRA Inspections: Key Focus Areas for US-Based Sites” »